Vaccinex Revenue and Competitors

Location

$65.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Vaccinex's estimated annual revenue is currently $12.6M per year.(i)
  • 0
  • Vaccinex's total funding is $65.9M.

Employee Data

    00

Vaccinex's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
Sr. VP, Clinical DevelopmentReveal Email/Phone
3
SVP, DevelopmentReveal Email/Phone
4
SVP, Discovery and Translational MedicineReveal Email/Phone
5
Director, Laboratory OperationsReveal Email/Phone
6
Director Antibody DiscoveryReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
SVP, Research and Chief Scientific OfficerReveal Email/Phone
9
Clinical Project ManagerReveal Email/Phone
10
CMC ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Vaccinex?

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. The company's strategy is to leverage its proprietary antibody discovery capabilities to develop its own pipeline of therapeutic antibody products, while utilizing near-term revenues from antibody collaborations to offset operating costs. Vaccinex's antibody platform is distinctive because it represents one of the only library-based antibody discovery technologies that can express complete, fully human antibodies in mammalian cells.

keywords:N/A

$65.9M

Total Funding

N/A

Number of Employees

$12.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vaccinex News

2022-03-30 - VACCINEX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)

VACCINEX, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K). Link copied.

2022-03-30 - Vaccinex Reports 2021 Financial Results and Provides ...

Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the...

2022-03-22 - Vaccinex, Inc. Announces Upcoming Presentation at the 2022 ...

About Vaccinex, Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases...

2008-02-26 - Life sciences briefing: Tuesday, Feb. 26, 2008

TODAY’S HEADLINES: Adnavance pulls in C$3.7M for molecular diagnostics, names new CEO (release) “Personalized medicine” co. Proprius sells to Cypress Bio for up to $75M (release) Vaccinex raises $25M in wake of GSK deal for antibody drugs (VentureWire) Cianna Medical receives $9M for breast- ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1541.6M0N/AN/A
#2
$0.1M1-80%N/A
#3
$0.1M1-97%N/A
#4
N/A1-67%N/A
#5
$0.3M20%N/A